Real-World Efficacy and Safety of Neuromyelitis Optica Spectrum Disorder Disease-Modifying Treatments
This study provides Class III evidence that, in patients with NMOSD, FDA-approved disease-modifying therapies are associated with lower relapse rates and fewer serious adverse events compared with rituximab.
Authors
- João Vitor Mahler (ORCID: https://orcid.org/0000-0002-0700-3517)
- Brian C. Healy (ORCID: https://orcid.org/0000-0001-5272-2425)
- Sathya Narasimhan
- Farrah Jasmine Mateen (ORCID: https://orcid.org/0000-0002-4293-8115)
- M Levy
- Philippe Bilodeau
- Mulan Jiang
- Avanteeka Ganguly
- Mattia Wruble Clark
- Jenna Bernice Harowitz
- Danielle Kei Pua
- Shamik Bhattacharyya
Institutions
- Boston Children's Hospital (US)
- Harvard University (US)
- Mass General Brigham (US)
Publication Details
- Journal
- Neurology Neuroimmunology & Neuroinflammation
- Published
- 2026-01-06
- DOI
- https://doi.org/10.1212/nxi.0000000000200536
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00